Obermatt Rankings
► UK Switzerland Germany
► Luxury Pharmaceuticals
► Swiss Banks
► Contact for detail info
Newsletter
Statements
Obermatt Ranking Pharmaceuticals
Obermatt's rankings are based on indexed performance and thus independent of subjective opinions and the effects of external economic factors. They enable an objective and independent comparison of executive performance and executive remuneration and compensation.
The better a company and its CEO performs in the ranking, the higher the company and the CEO ranks in the Obermatt Ranking. The rankings are used for:
- CEO Performance
- Investment Performance
- Remuneration Performance
Further insight into Obermatt's company and CEO rankings are available by contacting Obermatt.
Best Overall Performance (based on combined rank)
| Rank | Company | Combined Rank 2010 | Operating Rank 2010 | Investment Rank 2010 |
| 1 | Mylan | 66% | 65% | 67% |
| 2 | Pfizer | 64% | 90% | 38% |
| 3 | Novartis | 53% | 68% | 37% |
| 4 | Biogen Idec | 51% | 23% | 80% |
| 5 | Eli Lilly | 49% | 54% | 45% |
| 6 | Gilead Sciences | 48% | 85% | 10% |
| 7 | Abbott | 35% | 50% | 21% |
| 8 | Amgen | 34% | 42% | 26% |
| 9 | Johnson & Johnson | 33% | 32% | 33% |
| 10 | Roche | 21% | 35% | 8% |
List of assessed companies
| Abbott |
| Amgen |
| Biogen Idec |
| Eli Lilly |
| Gilead Sciences |
| Johnson & Johnson |
| Mylan |
| Novartis |
| Novartis - Consumer Health |
| Novartis - Sandoz |
| Novartis - Vaccines & Diagnostics |
| Novartis - Pharmaceuticals |
| Pfizer |
| Roche |
| Roche - Pharmaceuticals |
| Roche - Diagnostics |